213 related articles for article (PubMed ID: 35538491)
1. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.
Ascierto PA; Warner AB; Blank C; Caracò C; Demaria S; Gershenwald JE; Khushalani NI; Long GV; Luke JJ; Mehnert JM; Robert C; Rutkowski P; Tawbi HA; Osman I; Puzanov I
J Transl Med; 2022 May; 20(1):200. PubMed ID: 35538491
[TBL] [Abstract][Full Text] [Related]
2. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
Ascierto PA; Atkins MB; Eggermont AM; Gershenwald JE; Grob JJ; Hamid O; Sondak VK; Sosman JA; Tawbi HA; Weber JS; Caracò C; Osman I; Puzanov I
J Transl Med; 2021 Apr; 19(1):142. PubMed ID: 33827575
[TBL] [Abstract][Full Text] [Related]
3. The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.
Ascierto PA; Blank C; Eggermont AM; Garbe C; Gershenwald JE; Hamid O; Hauschild A; Luke JJ; Mehnert JM; Sosman JA; Tawbi HA; Mandalà M; Testori A; Caracò C; Osman I; Puzanov I
J Transl Med; 2023 Apr; 21(1):265. PubMed ID: 37072748
[TBL] [Abstract][Full Text] [Related]
4. The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.
Ascierto PA; Agarwala SS; Eggermont A; Gershenwald JE; Grob JJ; Hamid O; Michielin O; Postow M; Puzanov I; Zarour HM; Caracò C; Testori A
J Transl Med; 2020 Apr; 18(1):171. PubMed ID: 32299446
[TBL] [Abstract][Full Text] [Related]
5. The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.
Ascierto PA; Bruzzi P; Eggermont A; Hamid O; Tawbi HA; van Akkooi A; Testori A; Caracò C; Puzanov I; Perrone F
J Transl Med; 2019 May; 17(1):148. PubMed ID: 31077205
[TBL] [Abstract][Full Text] [Related]
6. The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020.
Ascierto PA; Brody J; Butterfield LH; Finn OJ; Goldberg J; Perrone F; Sullivan RJ; Fox BA; Hwu P; Puzanov I
J Transl Med; 2021 Apr; 19(1):144. PubMed ID: 33827609
[TBL] [Abstract][Full Text] [Related]
7. The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.
Ascierto PA; Caracò C; Gershenwald JE; Hamid O; Ross M; Sullivan RJ; Puzanov I
J Transl Med; 2018 Apr; 16(1):101. PubMed ID: 29665799
[TBL] [Abstract][Full Text] [Related]
8. The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022.
Ascierto PA; Brentjens R; Khleif SN; Odunsi K; Rezvani K; Ruella M; Sullivan RJ; Fox BA; Puzanov I
J Transl Med; 2023 Apr; 21(1):275. PubMed ID: 37087493
[TBL] [Abstract][Full Text] [Related]
9. The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.
Ascierto PA; Butterfield LH; Finn OJ; Futreal A; Hamid O; LaVallee T; Postow MA; Puzanov I; Sosman J; Fox BA; Hwu P
J Transl Med; 2022 Apr; 20(1):179. PubMed ID: 35449104
[TBL] [Abstract][Full Text] [Related]
10. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
11. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
12. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Ascierto PA; Agarwala SS; Warner AB; Ernstoff MS; Fox BA; Gajewski TF; Galon J; Garbe C; Gastman BR; Gershenwald JE; Kalinski P; Krogsgaard M; Leidner RS; Lo RS; Menzies AM; Michielin O; Poulikakos PI; Weber JS; Caracò C; Osman I; Puzanov I; Thurin M
J Transl Med; 2023 Jul; 21(1):508. PubMed ID: 37507765
[TBL] [Abstract][Full Text] [Related]
13. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
Ascierto PA; Puzanov I; Agarwala SS; Blank C; Carvajal RD; Demaria S; Dummer R; Ernstoff M; Ferrone S; Fox BA; Gajewski TF; Garbe C; Hwu P; Lo RS; Long GV; Luke JJ; Osman I; Postow MA; Sullivan RJ; Taube JM; Trinchieri G; Zarour HM; Caracò C; Thurin M
J Transl Med; 2020 Sep; 18(1):346. PubMed ID: 32894202
[TBL] [Abstract][Full Text] [Related]
14. The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019.
Ascierto PA; Bifulco C; Galon J; Garbe C; Khleif SN; McQuade J; Odunsi K; Okada H; Paulos CM; Quezada SA; Tawbi HA; Timmerman J; Trinchieri G; Butterfield LH; Puzanov I
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843491
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
An Q; Liu Z
BMC Cancer; 2019 Jan; 19(1):43. PubMed ID: 30626368
[TBL] [Abstract][Full Text] [Related]
16. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
[TBL] [Abstract][Full Text] [Related]
18. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto PA; Agarwala SS; Blank C; Caracò C; Carvajal RD; Ernstoff MS; Ferrone S; Fox BA; Gajewski TF; Garbe C; Grob JJ; Hamid O; Krogsgaard M; Lo RS; Lund AW; Madonna G; Michielin O; Neyns B; Osman I; Peters S; Poulikakos PI; Quezada SA; Reinfeld B; Zitvogel L; Puzanov I; Thurin M
J Transl Med; 2022 Sep; 20(1):391. PubMed ID: 36058945
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
20. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
